{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:46:36Z","timestamp":1794444396496,"version":"4.9.1"},"reference-count":143,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Systemic sclerosis (SSc) is a systemic, immune-mediated chronic disorder characterized by small vessel alterations and progressive fibrosis of the skin and internal organs. The combination of a predisposing genetic background and triggering factors that causes a persistent activation of immune system at microvascular and tissue level is thought to be the pathogenetic driver of SSc. Endothelial alterations with subsequent myofibroblast activation, excessive extracellular matrix (ECM) deposition, and unrestrained tissue fibrosis are the pathogenetic steps responsible for the clinical manifestations of this disease, which can be highly heterogeneous according to the different entity of each pathogenic step in individual subjects. Although substantial progress has been made in the management of SSc in recent years, disease-modifying therapies are still lacking. Several molecular pathways involved in SSc pathogenesis are currently under evaluation as possible therapeutic targets in clinical trials. These include drugs targeting fibrotic and metabolic pathways (e.g., TGF-\u03b2, autotaxin\/LPA, melanocortin, and mTOR), as well as molecules and cells involved in the persistent activation of the immune system (e.g., IL4\/IL13, IL23, JAK\/STAT, B cells, and plasma cells). In this review, we provide an overview of the most promising therapeutic targets that could improve the future clinical management of SSc.<\/jats:p>","DOI":"10.3390\/biomedicines10010163","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T23:17:07Z","timestamp":1642029427000},"page":"163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9867-2360","authenticated-orcid":false,"given":"Devis","family":"Benfaremo","sequence":"first","affiliation":[{"name":"Clinica Medica, Department of Internal Medicine, Ospedali Riuniti \u201cUmberto I-G.M. Lancisi-G. Salesi\u201d, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-2600","authenticated-orcid":false,"given":"Silvia","family":"Svegliati","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6364-7408","authenticated-orcid":false,"given":"Chiara","family":"Paolini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2823-6325","authenticated-orcid":false,"given":"Silvia","family":"Agarbati","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Moroncini","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Internal Medicine, Ospedali Riuniti \u201cUmberto I-G.M. Lancisi-G. Salesi\u201d, 60126 Ancona, Italy"},{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.22069","article-title":"Clinical differences between idiopathic and scleroderma-related pulmonary hypertension","volume":"54","author":"Fisher","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective Tissue Disease\u2013associated Pulmonary Arterial Hypertension in the Modern Treatment Era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5301\/jsrd.5000216","article-title":"Limited cutaneous systemic sclerosis: The unfairly neglected subset","volume":"1","author":"Allanore","year":"2016","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5152\/eurjrheum.2020.19131","article-title":"Putative functional pathogenic autoantibodies in systemic sclerosis","volume":"7","author":"Benfaremo","year":"2020","journal-title":"Eur. J. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.5301\/jsrd.5000265","article-title":"Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis","volume":"2","author":"Choy","year":"2017","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.autrev.2015.02.002","article-title":"Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?","volume":"14","author":"Iudici","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/2397198318808998","article-title":"Pulmonary arterial hypertension in systemic sclerosis: Diagnosis and treatment according to the European Society of Cardiology and European Respiratory Society 2015 guidelines","volume":"4","author":"Giordano","year":"2019","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcp174","article-title":"Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: A retrospective cohort study","volume":"103","author":"Nihtyanova","year":"2009","journal-title":"QJM Int. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.39865","article-title":"Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis","volume":"69","author":"Distler","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1038\/s41467-019-12760-y","article-title":"GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways","volume":"10","author":"Kerick","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/s41598-020-58741-w","article-title":"A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn\u2019s disease","volume":"10","author":"Ochoa","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/annrheumdis-2015-208154","article-title":"Influence of TYK2in systemic sclerosis susceptibility: A newlocusin the IL-12 pathway","volume":"75","author":"Guerra","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/annrheumdis-2021-219884","article-title":"Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes","volume":"80","author":"Kerick","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.imlet.2017.10.007","article-title":"Agonistic antibodies in systemic sclerosis","volume":"195","author":"Moroncini","year":"2018","journal-title":"Immunol. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_18","first-page":"75","article-title":"Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro","volume":"8","author":"Svegliati","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/art.39125","article-title":"Epitope Specificity Determines Pathogenicity and Detectability of Anti-Platelet-Derived Growth Factor Receptor \u03b1 Autoantibodies in Systemic Sclerosis","volume":"67","author":"Moroncini","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ab.2017.04.011","article-title":"Characterization of binding and quantification of human autoantibodies to PDGFR\u03b1 using a biosensor-based approach","volume":"528","author":"Moroncini","year":"2017","journal-title":"Anal. Biochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.39728","article-title":"Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti\u2212Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies","volume":"68","author":"Luchetti","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/BOR.0000000000000553","article-title":"T cells and cytokines in systemic sclerosis","volume":"30","author":"Fuschiotti","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3389\/fimmu.2018.02356","article-title":"Regulatory T Cells in Systemic Sclerosis","volume":"9","author":"Frantz","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1038\/s41598-019-41153-w","article-title":"Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients","volume":"9","author":"Chadli","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","article-title":"Toll-Like Receptor 4 Signaling Augments Transforming Growth Factor-\u03b2 Responses: A Novel Mechanism for Maintaining and Amplifying Fibrosis in Scleroderma","volume":"182","author":"Bhattacharyya","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11926-014-0474-z","article-title":"Emerging Roles of Innate Immune Signaling and Toll-Like Receptors in Fibrosis and Systemic Sclerosis","volume":"17","author":"Bhattacharyya","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"Lee","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jaci.2014.05.011","article-title":"IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice","volume":"134","author":"Li","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1073\/pnas.1315854111","article-title":"IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis","volume":"111","author":"Hams","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/art.27220","article-title":"A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"62","author":"Farina","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/imm.12910","article-title":"Implications of macrophage polarization in autoimmunity","volume":"154","author":"Funes","year":"2018","journal-title":"Immunology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Moroncini, G., Paolini, C., Orlando, F., Capelli, C., Grieco, A., Tonnini, C., Agarbati, S., Mondini, E., Saccomanno, S., and Goteri, G. (2018). Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196048"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/835948","article-title":"Role of Endothelial to Mesenchymal Transition in the Pathogenesis of the Vascular Alterations in Systemic Sclerosis","volume":"2013","author":"Jimenez","year":"2013","journal-title":"ISRN Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/01.RES.0000134644.89917.96","article-title":"Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients with Systemic Sclerosis","volume":"95","author":"Distler","year":"2004","journal-title":"Circ. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1165\/rcmb.2006-0353OC","article-title":"Endothelin-1 Induces Alveolar Epithelial\u2013Mesenchymal Transition through Endothelin Type A Receptor\u2013Mediated Production of TGF-\u03b21","volume":"37","author":"Jain","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1513\/pats.200601-004TK","article-title":"Epithelial Origin of Myofibroblasts during Fibrosis in the Lung","volume":"3","author":"Willis","year":"2006","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.22328","article-title":"Postnatal induction of transforming growth factor \u03b2 signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma","volume":"56","author":"Sonnylal","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2004592","article-title":"Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis","volume":"7","author":"Svegliati","year":"2014","journal-title":"Sci. Signal."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Fransen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2147\/VHRM.S4713","article-title":"Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient","volume":"5","author":"Valerio","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_43","first-page":"32","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: Results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Denton","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/0976-500X.149151","article-title":"Macitentan: An important addition to the treatment of pulmonary arterial hypertension","volume":"6","author":"Khadka","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","article-title":"Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials","volume":"315","author":"Khanna","year":"2016","journal-title":"JAMA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: The placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1183\/09031936.00124007","article-title":"Phosphodiesterase inhibitors for the treatment of pulmonary hypertension","volume":"32","author":"Wilkins","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: Results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-1979-7","article-title":"A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers","volume":"21","author":"Nagaraja","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir. Med."},{"key":"ref_52","first-page":"167","article-title":"OP0183 efficacy and safety of riociguat in patients with early diffuse cutaneous systemic sclerosis and interstitial lung disease (ssc-ild): Results from the phase iib rise-ssc study","volume":"78","author":"Distler","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the Treatment of Pulmonary Arterial Hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/17512433.2017.1322900","article-title":"Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: A pharmacology review","volume":"10","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/art.40242","article-title":"Efficacy and Safety of Selexipag in Adults With Raynaud\u2019s Phenomenon Secondary to Systemic Sclerosis","volume":"69","author":"Denton","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"Hoogen","year":"1996","journal-title":"Rheumatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A Randomized, Controlled Trial of Methotrexate versus Placebo in Early Diffuse Scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus Placebo in Scleroderma Lung Disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1007\/s10067-018-4171-6","article-title":"Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: Influence of the extent of inflammation on pulmonary function","volume":"37","author":"Hombergh","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/rheumatology\/kez487","article-title":"Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis","volume":"59","author":"Kersten","year":"2020","journal-title":"Rheumatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1016\/S2665-9913(20)30237-X","article-title":"Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): Open-label extension of a phase 2, double-blind randomised trial","volume":"2","author":"Chung","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2174\/1389201019666171226152448","article-title":"Biologics in Inflammatory Immune-mediated Systemic Diseases","volume":"18","author":"Moroncini","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: An open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_69","first-page":"142","article-title":"Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study","volume":"36","author":"Fraticelli","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s10067-020-05542-1","article-title":"Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: A systematic review and metaanalysis","volume":"40","author":"Borrirukwisitsak","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3899\/jrheum.111423","article-title":"Interleukin 6 in Systemic Sclerosis and Potential Implications for Targeted Therapy","volume":"39","author":"Muangchan","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis","volume":"40","author":"Sestini","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","article-title":"Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis","volume":"71","author":"Khan","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Investigators, the focuSSced Tocilizumab Prevents Progression of Early Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2397198320903208","article-title":"Treatment of systemic sclerosis\u2013associated interstitial lung disease: Lessons from clinical trials","volume":"5","author":"Roofeh","year":"2020","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: A subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.24395","article-title":"The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","article-title":"Targeting the Cannabinoid Pathway Limits the Development of Fibrosis and Autoimmunity in a Mouse Model of Systemic Sclerosis","volume":"177","author":"Servettaz","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e00394","DOI":"10.1002\/prp2.394","article-title":"Ajulemic acid: Potential treatment for chronic inflammation","volume":"6","author":"Burstein","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_86","first-page":"52","article-title":"OP0006 Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in an open-label extension of trial jbt101-ssc-001","volume":"77","author":"Spiera","year":"2018","journal-title":"Ann. Rheum. Dis. 2018"},{"key":"ref_87","first-page":"245","article-title":"OP0325 safety and efficacy of lenabasum in an open-label extension of a phase 2 study in diffuse cutaneous systemic sclerosis subjects (dcssc)","volume":"78","author":"Spiera","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1023\/A:1007068313370","article-title":"Anti-Inflammatory Effect of Pirfenidone in the Bleomycin-Hamster Model of Lung Inflammation","volume":"24","author":"Iyer","year":"2000","journal-title":"Inflammation"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: The LOTUSS Trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_92","first-page":"200","article-title":"OP0243 efficacy of pirfenidone in systemic sclerosis related interstitial lung disease\u2014a randomised controlled trial","volume":"78","author":"Acharya","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1574886310666151014115532","article-title":"Biologic Therapy in Psoriasis: Safety Profile","volume":"11","author":"Campanati","year":"2016","journal-title":"Curr. Drug Saf."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/1721727X1301100218","article-title":"Adalimumab Modulates Angiogenesis in Psoriatic Skin","volume":"11","author":"Campanati","year":"2013","journal-title":"Eur. J. Inflamm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cellsig.2011.10.010","article-title":"Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1\/DUSP-1","volume":"24","author":"Valente","year":"2012","journal-title":"Cell. Signal."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.4049\/jimmunol.1100591","article-title":"Impaired IL-17 Signaling Pathway Contributes to the Increased Collagen Expression in Scleroderma Fibroblasts","volume":"188","author":"Nakashima","year":"2012","journal-title":"J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","article-title":"Increased Interleukin-17 Production in Patients with Systemic Sclerosis","volume":"43","author":"Kurasawa","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.4049\/jimmunol.1004081","article-title":"Blocking IL-17A Promotes the Resolution of Pulmonary Inflammation and Fibrosis Via TGF-\u03b21\u2013Dependent and \u2013Independent Mechanisms","volume":"187","author":"Mi","year":"2011","journal-title":"J. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Benfaremo, D., and Gabrielli, A. (2020). Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?. Cells, 9.","DOI":"10.3390\/cells9010077"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: Danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the Treatment of Early Diffuse Systemic Sclerosis","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/biof.1117","article-title":"Role of interleukin-13 in fibrosis, particularly systemic sclerosis","volume":"39","year":"2013","journal-title":"BioFactors"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1801130","DOI":"10.1183\/13993003.01130-2018","article-title":"SAR156597 in idiopathic pulmonary fibrosis: A phase 2 placebo-controlled study (DRI11772)","volume":"52","author":"Raghu","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"F142","DOI":"10.1152\/ajprenal.00320.2009","article-title":"Noncanonical TGF-\u03b2 pathways, mTORC1 and Abl, in renal interstitial fibrogenesis","volume":"298","author":"Wang","year":"2010","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.27498","article-title":"Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis","volume":"62","author":"Yoshizaki","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/art.24986","article-title":"Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study","volume":"60","author":"Su","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2397198319865367","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","volume":"5","author":"Wang","year":"2020","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","article-title":"Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis","volume":"60","author":"You","year":"2021","journal-title":"Rheumatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","article-title":"Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis","volume":"55","author":"Raja","year":"2015","journal-title":"Rheumatology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","article-title":"Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature","volume":"16","author":"Sanges","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"Dhimolea","year":"2012","journal-title":"mAbs"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fimmu.2019.02025","article-title":"The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/bcp.13669","article-title":"In vivoaffinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody","volume":"84","author":"Reid","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.5301\/jsrd.5000266","article-title":"Interleukin-6 and Related Proteins as Biomarkers in Systemic Sclerosis","volume":"2","author":"Denton","year":"2017","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1002\/art.39797","article-title":"An Autotaxin\/Lysophosphatidic Acid\/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis","volume":"68","author":"Castelino","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/annrheumdis-2014-eular.2979","article-title":"OP0241 Autotaxin is Over-Expressed in Systemic Sclerosis (SSC) Skin, Mediates Bleomycin-Induced Dermal Fibrosis via IL-6, and is A Target for SSC Therapy","volume":"73","author":"Castelino","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fmed.2018.00180","article-title":"Autotaxin in Pathophysiology and Pulmonary Fibrosis","volume":"5","author":"Ninou","year":"2018","journal-title":"Front. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.4049\/jimmunol.1602142","article-title":"Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10","volume":"198","author":"Weiss","year":"2017","journal-title":"J. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.3390\/ijms13078293","article-title":"Fasudil, a Rho-Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice","volume":"13","author":"Jiang","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Dinparastisaleh, R., and Mirsaeidi, M. (2021). Antifibrotic and Anti-Inflammatory Actions of \u03b1-Melanocytic Hormone: New Roles for an Old Player. Pharmaceuticals, 14.","DOI":"10.3390\/ph14010045"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7555\/JBR.31.20170034","article-title":"Transforming growth factor-\u03b2 signaling in systemic sclerosis","volume":"32","author":"Ayers","year":"2018","journal-title":"J. Biomed. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/annrheumdis-2020-eular.1753","article-title":"THU0329 safety, target engagement, and initial efficacy of avid200, a first-in-class potent and isoform-selective inhibitor of tgf-beta 1 and 3, in patients with diffuse cutaneous systemic sclerosis (dcssc): A phase 1 dose escalation study","volume":"79","author":"Lafyatis","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1378\/chest.109.3.780","article-title":"Increased Expression of Platelet-Derived Growth Factor A and Insulin-Like Growth Factor-I in BAL Cells During the Development of Bleomycin-Induced Pulmonary Fibrosis in Mice","volume":"109","author":"Maeda","year":"1996","journal-title":"Chest"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.3899\/jrheum.080340","article-title":"Elevated Serum Insulin-like Growth Factor (IGF-1) and IGF Binding Protein-3 Levels in Patients with Systemic Sclerosis: Possible Role in Development of Fibrosis","volume":"35","author":"Hamaguchi","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1527-3466.2001.tb00058.x","article-title":"Ifetroban sodium: An effective TxA2\/PGH2 receptor antagonist","volume":"19","author":"Rosenfeld","year":"2006","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3389\/fimmu.2018.02938","article-title":"Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?","volume":"9","author":"Rozier","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1124\/jpet.110.175901","article-title":"Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist","volume":"336","author":"Swaney","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/art.40547","article-title":"Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis","volume":"70","author":"Allanore","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: A phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/19420862.2015.1007810","article-title":"Molecular basis for antagonistic activity of anifrolumab, an anti-interferon\u2013\u03b1 receptor 1 antibody","volume":"7","author":"Peng","year":"2015","journal-title":"mAbs"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-Interferon-\u03b1 Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/ard.2010.137935","article-title":"The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: An open-label study","volume":"70","author":"Becker","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/annrheumdis-2013-203674","article-title":"Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): A phase II double-blind placebo-controlled trial","volume":"73","author":"Quillinan","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.3389\/fimmu.2018.02434","article-title":"Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis","volume":"9","author":"Bhattacharyya","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-010-0142-x","article-title":"Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials","volume":"13","author":"Iwamoto","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"Akhmetshina","year":"2008","journal-title":"FASEB J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: A phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdu474","article-title":"Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: The randomised phase I\/II POSEIDON trial","volume":"26","author":"Martens","year":"2015","journal-title":"Ann. Oncol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/1\/163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:14:51Z","timestamp":1760364891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/1\/163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":143,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["biomedicines10010163"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10010163","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]}}}